Juvenile Dermatomyositis: Immunopathogenesis, Role of Myositis‐Specific Autoantibodies, and Review of Rituximab Use
Identifieur interne : 000207 ( Istex/Corpus ); précédent : 000206; suivant : 000208Juvenile Dermatomyositis: Immunopathogenesis, Role of Myositis‐Specific Autoantibodies, and Review of Rituximab Use
Auteurs : Yvonne E. Chiu ; Dominic O. CoSource :
- Pediatric Dermatology [ 0736-8046 ] ; 2011-07.
English descriptors
- Teeft :
- Amyopathic dermatomyositis, Antisynthetase, Antisynthetase autoantibodies, Arthritis, Arthritis rheum, Autoantibody, Autoimmune, Autoimmune disease, Autoimmune diseases, Cell transplantation, Chiu, Clinical phenotype, Cutaneous, Cyclosporine, Dendritic, Dendritic cells, Dermatology, Dermatomyositis, High levels, Humoral immunity, Idiopathic, Idiopathic myopathies, Interstitial lung disease, Ivig, Ivig prednisone, Juvenile dermatomyositis, Lung disease, Lymphoid, Malignancy, Melanoma gene, Methotrexate, Methylprednisolone, Muscle strength, Myopathy, Myositis, Ndings, Pathogenesis, Pediatric, Pediatric dermatology, Peripheral blood, Plasma cells, Plasmacytoid, Plasmacytoid dendritic cells, Polymyositis, Rheum, Rheumatoid, Rheumatoid arthritis, Rheumatol, Rheumatology, Rituximab, Rituximab therapy, Signal recognition particle, Synthetase, Viral infections, Wedderburn.
Abstract
Abstract: Juvenile dermatomyositis (JDM) is an autoimmune disease of the skin and muscle that affects children. The etiology is poorly understood, but genetic susceptibility, environmental triggers, and abnormal immune responses are each thought to play a part. T cells have traditionally been implicated in the immunopathogenesis of JDM, but dendritic cells, B cells, and microchimerism are increasingly associated. Additionally, myositis‐specific autoantibodies (MSA) can be present in the sera of affected patients and may correlate with distinct clinical phenotypes. Given the role of humoral immunity and MSA, there has been recent interest in the use of rituximab to treat JDM. Early results are mixed, but it is hoped that a prospective clinical trial will shed light on the issue in the near future.
Url:
DOI: 10.1111/j.1525-1470.2011.01501.x
Links to Exploration step
ISTEX:C0CCE2C633CE41CF2E6FAF8D1F7937E04CA4A466Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Juvenile Dermatomyositis: Immunopathogenesis, Role of Myositis‐Specific Autoantibodies, and Review of Rituximab Use</title><author><name sortKey="Chiu, Yvonne E" sort="Chiu, Yvonne E" uniqKey="Chiu Y" first="Yvonne E." last="Chiu">Yvonne E. Chiu</name><affiliation><mods:affiliation>Division of Pediatric Dermatology, Department of Dermatology, Milwaukee, Wisconsin</mods:affiliation></affiliation></author><author><name sortKey="Co, Dominic O" sort="Co, Dominic O" uniqKey="Co D" first="Dominic O." last="Co">Dominic O. Co</name><affiliation><mods:affiliation>Section of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C0CCE2C633CE41CF2E6FAF8D1F7937E04CA4A466</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1111/j.1525-1470.2011.01501.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-L2HMX7R5-8/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000207</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000207</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Juvenile Dermatomyositis: Immunopathogenesis, Role of Myositis‐Specific Autoantibodies, and Review of Rituximab Use</title><author><name sortKey="Chiu, Yvonne E" sort="Chiu, Yvonne E" uniqKey="Chiu Y" first="Yvonne E." last="Chiu">Yvonne E. Chiu</name><affiliation><mods:affiliation>Division of Pediatric Dermatology, Department of Dermatology, Milwaukee, Wisconsin</mods:affiliation></affiliation></author><author><name sortKey="Co, Dominic O" sort="Co, Dominic O" uniqKey="Co D" first="Dominic O." last="Co">Dominic O. Co</name><affiliation><mods:affiliation>Section of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Pediatric Dermatology</title><title level="j" type="alt">PEDIATRIC DERMATOLOGY</title><idno type="ISSN">0736-8046</idno><idno type="eISSN">1525-1470</idno><imprint><biblScope unit="vol">28</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="357">357</biblScope><biblScope unit="page" to="367">367</biblScope><biblScope unit="page-count">11</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2011-07">2011-07</date></imprint><idno type="ISSN">0736-8046</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0736-8046</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Amyopathic dermatomyositis</term><term>Antisynthetase</term><term>Antisynthetase autoantibodies</term><term>Arthritis</term><term>Arthritis rheum</term><term>Autoantibody</term><term>Autoimmune</term><term>Autoimmune disease</term><term>Autoimmune diseases</term><term>Cell transplantation</term><term>Chiu</term><term>Clinical phenotype</term><term>Cutaneous</term><term>Cyclosporine</term><term>Dendritic</term><term>Dendritic cells</term><term>Dermatology</term><term>Dermatomyositis</term><term>High levels</term><term>Humoral immunity</term><term>Idiopathic</term><term>Idiopathic myopathies</term><term>Interstitial lung disease</term><term>Ivig</term><term>Ivig prednisone</term><term>Juvenile dermatomyositis</term><term>Lung disease</term><term>Lymphoid</term><term>Malignancy</term><term>Melanoma gene</term><term>Methotrexate</term><term>Methylprednisolone</term><term>Muscle strength</term><term>Myopathy</term><term>Myositis</term><term>Ndings</term><term>Pathogenesis</term><term>Pediatric</term><term>Pediatric dermatology</term><term>Peripheral blood</term><term>Plasma cells</term><term>Plasmacytoid</term><term>Plasmacytoid dendritic cells</term><term>Polymyositis</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatol</term><term>Rheumatology</term><term>Rituximab</term><term>Rituximab therapy</term><term>Signal recognition particle</term><term>Synthetase</term><term>Viral infections</term><term>Wedderburn</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Juvenile dermatomyositis (JDM) is an autoimmune disease of the skin and muscle that affects children. The etiology is poorly understood, but genetic susceptibility, environmental triggers, and abnormal immune responses are each thought to play a part. T cells have traditionally been implicated in the immunopathogenesis of JDM, but dendritic cells, B cells, and microchimerism are increasingly associated. Additionally, myositis‐specific autoantibodies (MSA) can be present in the sera of affected patients and may correlate with distinct clinical phenotypes. Given the role of humoral immunity and MSA, there has been recent interest in the use of rituximab to treat JDM. Early results are mixed, but it is hoped that a prospective clinical trial will shed light on the issue in the near future.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>autoantibody</json:string><json:string>rituximab</json:string><json:string>dermatomyositis</json:string><json:string>juvenile dermatomyositis</json:string><json:string>cutaneous</json:string><json:string>methotrexate</json:string><json:string>myositis</json:string><json:string>dendritic</json:string><json:string>myopathy</json:string><json:string>arthritis rheum</json:string><json:string>ivig</json:string><json:string>antisynthetase</json:string><json:string>autoimmune</json:string><json:string>rheum</json:string><json:string>idiopathic</json:string><json:string>synthetase</json:string><json:string>dermatology</json:string><json:string>methylprednisolone</json:string><json:string>pediatric</json:string><json:string>rheumatol</json:string><json:string>peripheral blood</json:string><json:string>chiu</json:string><json:string>cyclosporine</json:string><json:string>plasmacytoid</json:string><json:string>pediatric dermatology</json:string><json:string>ndings</json:string><json:string>rheumatoid arthritis</json:string><json:string>rheumatoid</json:string><json:string>lymphoid</json:string><json:string>rheumatology</json:string><json:string>wedderburn</json:string><json:string>antisynthetase autoantibodies</json:string><json:string>idiopathic myopathies</json:string><json:string>autoimmune diseases</json:string><json:string>dendritic cells</json:string><json:string>plasmacytoid dendritic cells</json:string><json:string>arthritis</json:string><json:string>humoral immunity</json:string><json:string>interstitial lung disease</json:string><json:string>clinical phenotype</json:string><json:string>lung disease</json:string><json:string>autoimmune disease</json:string><json:string>viral infections</json:string><json:string>pathogenesis</json:string><json:string>polymyositis</json:string><json:string>malignancy</json:string><json:string>signal recognition particle</json:string><json:string>ivig prednisone</json:string><json:string>muscle strength</json:string><json:string>cell transplantation</json:string><json:string>rituximab therapy</json:string><json:string>plasma cells</json:string><json:string>amyopathic dermatomyositis</json:string><json:string>high levels</json:string><json:string>melanoma gene</json:string></teeft></keywords><author><json:item><name>Yvonne E. Chiu M.D.</name><affiliations><json:string>Division of Pediatric Dermatology, Department of Dermatology, Milwaukee, Wisconsin</json:string></affiliations></json:item><json:item><name>Dominic O. Co M.D., Ph.D.</name><affiliations><json:string>Section of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin</json:string></affiliations></json:item></author><articleId><json:string>PDE1501</json:string></articleId><arkIstex>ark:/67375/WNG-L2HMX7R5-8</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>Abstract: Juvenile dermatomyositis (JDM) is an autoimmune disease of the skin and muscle that affects children. The etiology is poorly understood, but genetic susceptibility, environmental triggers, and abnormal immune responses are each thought to play a part. T cells have traditionally been implicated in the immunopathogenesis of JDM, but dendritic cells, B cells, and microchimerism are increasingly associated. Additionally, myositis‐specific autoantibodies (MSA) can be present in the sera of affected patients and may correlate with distinct clinical phenotypes. Given the role of humoral immunity and MSA, there has been recent interest in the use of rituximab to treat JDM. Early results are mixed, but it is hoped that a prospective clinical trial will shed light on the issue in the near future.</abstract><qualityIndicators><score>8.464</score><pdfWordCount>5310</pdfWordCount><pdfCharCount>38109</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>11</pdfPageCount><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><pdfWordsPerPage>483</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>122</abstractWordCount><abstractCharCount>808</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Juvenile Dermatomyositis: Immunopathogenesis, Role of Myositis‐Specific Autoantibodies, and Review of Rituximab Use</title><pmid><json:string>21793879</json:string></pmid><genre><json:string>review-article</json:string></genre><host><title>Pediatric Dermatology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1525-1470</json:string></doi><issn><json:string>0736-8046</json:string></issn><eissn><json:string>1525-1470</json:string></eissn><publisherId><json:string>PDE</json:string></publisherId><volume>28</volume><issue>4</issue><pages><first>357</first><last>367</last><total>11</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>REVIEW ARTICLE</value></json:item><json:item><value>REVIEW ARTICLE</value></json:item></subject></host><namedEntities><unitex><date><json:string>2011</json:string><json:string>1997</json:string><json:string>2002</json:string><json:string>2007</json:string></date><geogName></geogName><orgName><json:string>Wiley Periodicals, Inc.</json:string><json:string>Division of Pediatric Dermatology</json:string><json:string>Department of Dermatology, Milwaukee, Wisconsin, Section of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin Abstract</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Studies</json:string><json:string>Dominic O. Co</json:string><json:string>Yvonne E. Chiu</json:string></persName><placeName><json:string>United States</json:string><json:string>Milwaukee</json:string><json:string>Watertown</json:string><json:string>WI</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Rider et al</json:string><json:string>AsimilarstudybyFeldman et al</json:string><json:string>Oddis et al</json:string><json:string>Department of Dermatology, Medical College of Wisconsin, 8701</json:string><json:string>Wedderburn et al</json:string><json:string>van Vollenhoven et al</json:string><json:string>Gunawardena et al</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-L2HMX7R5-8</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - pediatrics</json:string><json:string>2 - dermatology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - dermatology & venereal diseases</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Dermatology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Pediatrics, Perinatology, and Child Health</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1111/j.1525-1470.2011.01501.x</json:string></doi><id>C0CCE2C633CE41CF2E6FAF8D1F7937E04CA4A466</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-L2HMX7R5-8/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-L2HMX7R5-8/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-L2HMX7R5-8/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Juvenile Dermatomyositis: Immunopathogenesis, Role of Myositis‐Specific Autoantibodies, and Review of Rituximab Use</title><title level="a" type="short">Juvenile Dermatomyositis: A Review</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><licence>© 2011 Wiley Periodicals, Inc.</licence></availability><date type="published" when="2011-07"></date></publicationStmt><notesStmt><note type="content-type" subtype="review-article" source="reviewArticle" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="review-article"><analytic><title level="a" type="main">Juvenile Dermatomyositis: Immunopathogenesis, Role of Myositis‐Specific Autoantibodies, and Review of Rituximab Use</title><title level="a" type="short">Juvenile Dermatomyositis: A Review</title><author xml:id="author-0000"><persName><forename type="first">Yvonne E.</forename><surname>Chiu</surname><roleName type="degree">M.D.</roleName></persName><affiliation><orgName type="department">Division of Pediatric Dermatology</orgName><orgName type="department">Department of Dermatology</orgName><address><addrLine>Milwaukee</addrLine><addrLine>Wisconsin</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Dominic O.</forename><surname>Co</surname><roleName type="degree">M.D., Ph.D.</roleName></persName><affiliation><orgName type="department">Section of Rheumatology</orgName><orgName type="division">Department of Pediatrics</orgName><orgName type="institution">Medical College of Wisconsin</orgName><address><addrLine>Milwaukee</addrLine><addrLine>Wisconsin</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><idno type="istex">C0CCE2C633CE41CF2E6FAF8D1F7937E04CA4A466</idno><idno type="ark">ark:/67375/WNG-L2HMX7R5-8</idno><idno type="DOI">10.1111/j.1525-1470.2011.01501.x</idno><idno type="unit">PDE1501</idno><idno type="toTypesetVersion">file:PDE.PDE1501.pdf</idno></analytic><monogr><title level="j" type="main">Pediatric Dermatology</title><title level="j" type="alt">PEDIATRIC DERMATOLOGY</title><idno type="pISSN">0736-8046</idno><idno type="eISSN">1525-1470</idno><idno type="book-DOI">10.1111/(ISSN)1525-1470</idno><idno type="book-part-DOI">10.1111/pde.2011.28.issue-4</idno><idno type="product">PDE</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">28</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="357">357</biblScope><biblScope unit="page" to="367">367</biblScope><biblScope unit="page-count">11</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2011-07"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><p><hi rend="bold">Abstract: </hi> Juvenile dermatomyositis (JDM) is an autoimmune disease of the skin and muscle that affects children. The etiology is poorly understood, but genetic susceptibility, environmental triggers, and abnormal immune responses are each thought to play a part. T cells have traditionally been implicated in the immunopathogenesis of JDM, but dendritic cells, B cells, and microchimerism are increasingly associated. Additionally, myositis‐specific autoantibodies (MSA) can be present in the sera of affected patients and may correlate with distinct clinical phenotypes. Given the role of humoral immunity and MSA, there has been recent interest in the use of rituximab to treat JDM. Early results are mixed, but it is hoped that a prospective clinical trial will shed light on the issue in the near future.</p></abstract><textClass><keywords rend="tocHeading1"><term>REVIEW ARTICLE</term></keywords><keywords rend="articleCategory"><term>REVIEW ARTICLE</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-L2HMX7R5-8/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1525-1470</doi><issn type="print">0736-8046</issn><issn type="electronic">1525-1470</issn><idGroup><id type="product" value="PDE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="PEDIATRIC DERMATOLOGY">Pediatric Dermatology</title></titleGroup></publicationMeta><publicationMeta level="part" position="07104"><doi origin="wiley">10.1111/pde.2011.28.issue-4</doi><numberingGroup><numbering type="journalVolume" number="28">28</numbering><numbering type="journalIssue" number="4">4</numbering></numberingGroup><coverDate startDate="2011-07">July/August 2011</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="1" status="forIssue"><doi origin="wiley">10.1111/j.1525-1470.2011.01501.x</doi><idGroup><id type="unit" value="PDE1501"></id></idGroup><countGroup><count type="pageTotal" number="11"></count></countGroup><titleGroup><title type="tocHeading1">REVIEW ARTICLE</title><title type="articleCategory">REVIEW ARTICLE</title></titleGroup><copyright>© 2011 Wiley Periodicals, Inc.</copyright><eventGroup><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.5.2 mode:FullText" date="2011-07-24"></event><event type="firstOnline" date="2011-07-24"></event><event type="publishedOnlineFinalForm" date="2011-07-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-06"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-03"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="357">357</numbering><numbering type="pageLast" number="367">367</numbering></numberingGroup><correspondenceTo>Address correspondence to Yvonne E. Chiu, M.D., Division of Pediatric Dermatology, Department of Dermatology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, or e‐mail: <email>ychiu@mcw.edu</email>.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:PDE.PDE1501.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count></countGroup><titleGroup><title type="main">Juvenile Dermatomyositis: Immunopathogenesis, Role of Myositis‐Specific Autoantibodies, and Review of Rituximab Use</title><title type="shortAuthors">Chiu and Co</title><title type="short">Juvenile Dermatomyositis: A Review</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>Yvonne E.</givenNames><familyName>Chiu</familyName><degrees>M.D.</degrees></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>Dominic O.</givenNames><familyName>Co</familyName><degrees>M.D., Ph.D.</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="US"><unparsedAffiliation>Division of Pediatric Dermatology, Department of Dermatology, Milwaukee, Wisconsin</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="US"><unparsedAffiliation>Section of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>Abstract: </b> Juvenile dermatomyositis (JDM) is an autoimmune disease of the skin and muscle that affects children. The etiology is poorly understood, but genetic susceptibility, environmental triggers, and abnormal immune responses are each thought to play a part. T cells have traditionally been implicated in the immunopathogenesis of JDM, but dendritic cells, B cells, and microchimerism are increasingly associated. Additionally, myositis‐specific autoantibodies (MSA) can be present in the sera of affected patients and may correlate with distinct clinical phenotypes. Given the role of humoral immunity and MSA, there has been recent interest in the use of rituximab to treat JDM. Early results are mixed, but it is hoped that a prospective clinical trial will shed light on the issue in the near future.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Juvenile Dermatomyositis: Immunopathogenesis, Role of Myositis‐Specific Autoantibodies, and Review of Rituximab Use</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Juvenile Dermatomyositis: A Review</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Juvenile Dermatomyositis: Immunopathogenesis, Role of Myositis‐Specific Autoantibodies, and Review of Rituximab Use</title></titleInfo><name type="personal"><namePart type="given">Yvonne E.</namePart><namePart type="family">Chiu</namePart><namePart type="termsOfAddress">M.D.</namePart><affiliation>Division of Pediatric Dermatology, Department of Dermatology, Milwaukee, Wisconsin</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dominic O.</namePart><namePart type="family">Co</namePart><namePart type="termsOfAddress">M.D., Ph.D.</namePart><affiliation>Section of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2011-07</dateIssued><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">0</extent><extent unit="tables">2</extent></physicalDescription><abstract lang="en">Abstract: Juvenile dermatomyositis (JDM) is an autoimmune disease of the skin and muscle that affects children. The etiology is poorly understood, but genetic susceptibility, environmental triggers, and abnormal immune responses are each thought to play a part. T cells have traditionally been implicated in the immunopathogenesis of JDM, but dendritic cells, B cells, and microchimerism are increasingly associated. Additionally, myositis‐specific autoantibodies (MSA) can be present in the sera of affected patients and may correlate with distinct clinical phenotypes. Given the role of humoral immunity and MSA, there has been recent interest in the use of rituximab to treat JDM. Early results are mixed, but it is hoped that a prospective clinical trial will shed light on the issue in the near future.</abstract><relatedItem type="host"><titleInfo><title>Pediatric Dermatology</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>REVIEW ARTICLE</topic><topic>REVIEW ARTICLE</topic></subject><identifier type="ISSN">0736-8046</identifier><identifier type="eISSN">1525-1470</identifier><identifier type="DOI">10.1111/(ISSN)1525-1470</identifier><identifier type="PublisherID">PDE</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>357</start><end>367</end><total>11</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry</title></titleInfo><name type="personal"><namePart type="given">EP</namePart><namePart type="family">Mendez</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Lipton</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Ramsey‐Goldman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mendez EP, Lipton R, Ramsey‐Goldman R et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003;49:300.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>300</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>300</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies</title></titleInfo><name type="personal"><namePart type="given">EM</namePart><namePart type="family">Dugan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AM</namePart><namePart type="family">Huber</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FW</namePart><namePart type="family">Miller</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dugan EM, Huber AM, Miller FW et al. Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J 2009;15:1.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>1</start></extent></part><relatedItem type="host"><titleInfo><title>Dermatol Online J</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>1</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>A systematic review of juvenile‐onset clinically amyopathic dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Gerami</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HW</namePart><namePart type="family">Walling</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Lewis</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gerami P, Walling HW, Lewis J et al. A systematic review of juvenile‐onset clinically amyopathic dermatomyositis. Br J Dermatol 2007;157:637–644.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>157</number></detail><extent unit="pages"><start>637</start><end>644</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>157</number></detail><extent unit="pages"><start>637</start><end>644</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment</title></titleInfo><name type="personal"><namePart type="given">AM</namePart><namePart type="family">Huber</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Huber AM. Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment. Paediatr Drugs 2009;11:361.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>361</start></extent></part><relatedItem type="host"><titleInfo><title>Paediatr Drugs</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>361</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment</title></titleInfo><name type="personal"><namePart type="given">LR</namePart><namePart type="family">Wedderburn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LG</namePart><namePart type="family">Rider</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wedderburn LR, Rider LG. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol 2009;23:665.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>665</start></extent></part><relatedItem type="host"><titleInfo><title>Best Pract Res Clin Rheumatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>665</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Vascular pathology in dermatomyositis and anatomic relations to myopathology</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Pestronk</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RE</namePart><namePart type="family">Schmidt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Choksi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pestronk A, Schmidt RE, Choksi R. Vascular pathology in dermatomyositis and anatomic relations to myopathology. Muscle Nerve 2010;42:53–61.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>53</start><end>61</end></extent></part><relatedItem type="host"><titleInfo><title>Muscle Nerve</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>53</start><end>61</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications</title></titleInfo><name type="personal"><namePart type="given">SA</namePart><namePart type="family">Greenberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007;69:2008–2019.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><extent unit="pages"><start>2008</start><end>2019</end></extent></part><relatedItem type="host"><titleInfo><title>Neurology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><extent unit="pages"><start>2008</start><end>2019</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Expression of immunoreactive major histocompatibility complex products in human skeletal muscles</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Karpati</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Pouliot</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Carpenter</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 1988;23:64–72.</note><part><date>1988</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>64</start><end>72</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Neurol</title></titleInfo><part><date>1988</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>64</start><end>72</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Extranodal lymphoid microstructures in inflamed muscle and disease severity of new‐onset juvenile dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">CM</namePart><namePart type="family">López De Padilla</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AN</namePart><namePart type="family">Vallejo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Lacomis</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">López De Padilla CM, Vallejo AN, Lacomis D et al. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new‐onset juvenile dermatomyositis. Arthritis Rheum 2009;60:1160–1172.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1160</start><end>1172</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1160</start><end>1172</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Caproni</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Torchia</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Cardinali</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Caproni M, Torchia D, Cardinali C et al. Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis. Br J Dermatol 2004;151:784–791.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>151</number></detail><extent unit="pages"><start>784</start><end>791</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>151</number></detail><extent unit="pages"><start>784</start><end>791</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells</title></titleInfo><name type="personal"><namePart type="given">AER</namePart><namePart type="family">Fasth</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Dastmalchi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Rahbar</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fasth AER, Dastmalchi M, Rahbar A et al. T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol 2009;183:4792–4799.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>183</number></detail><extent unit="pages"><start>4792</start><end>4799</end></extent></part><relatedItem type="host"><titleInfo><title>J Immunol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>183</number></detail><extent unit="pages"><start>4792</start><end>4799</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Flow cytometric analysis of lymphocyte subpopulations and TH1/TH2 balance in patients with polymyositis and dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">W</namePart><namePart type="family">Ishii</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Matsuda</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Shimojima</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ishii W, Matsuda M, Shimojima Y et al. Flow cytometric analysis of lymphocyte subpopulations and TH1/TH2 balance in patients with polymyositis and dermatomyositis. Intern Med 2008;47:1593–1599.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>1593</start><end>1599</end></extent></part><relatedItem type="host"><titleInfo><title>Intern Med</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>1593</start><end>1599</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Aleksza</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Szegedi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Antal‐Szalmás</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Aleksza M, Szegedi A, Antal‐Szalmás P et al. Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis. Ann Rheum Dis 2005;64:1485–1489.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>1485</start><end>1489</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>1485</start><end>1489</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Interleukin‐6 and type I interferon‐regulated genes and chemokines mark disease activity in dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Bilgic</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SR</namePart><namePart type="family">Ytterberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Amin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bilgic H, Ytterberg SR, Amin S et al. Interleukin‐6 and type I interferon‐regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009;60:3436–3446.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>3436</start><end>3446</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>3436</start><end>3446</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Interleukin‐17 increases the effects of IL‐1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Chevrel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Page</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Granet</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chevrel G, Page G, Granet C et al. Interleukin‐17 increases the effects of IL‐1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 2003;137:125–133.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>137</number></detail><extent unit="pages"><start>125</start><end>133</end></extent></part><relatedItem type="host"><titleInfo><title>J Neuroimmunol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>137</number></detail><extent unit="pages"><start>125</start><end>133</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>FOXP3+ regulatory T cells in the human immune system</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Sakaguchi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Miyara</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Costantino</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sakaguchi S, Miyara M, Costantino CM et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010;10:490–500.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>490</start><end>500</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Rev Immunol</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>490</start><end>500</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>FOXP3+ T regulatory cells in idiopathic inflammatory myopathies</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Waschbisch</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Schwab</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Ruck</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Waschbisch A, Schwab N, Ruck T et al. FOXP3+ T regulatory cells in idiopathic inflammatory myopathies. J Neuroimmunol 2010;225:137–142.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>225</number></detail><extent unit="pages"><start>137</start><end>142</end></extent></part><relatedItem type="host"><titleInfo><title>J Neuroimmunol</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>225</number></detail><extent unit="pages"><start>137</start><end>142</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Role of regulatory T cells in a new mouse model of experimental autoimmune myositis</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Allenbach</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Solly</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Grégoire</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Allenbach Y, Solly S, Grégoire S et al. Role of regulatory T cells in a new mouse model of experimental autoimmune myositis. Am J Pathol 2009;174:989–998.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>174</number></detail><extent unit="pages"><start>989</start><end>998</end></extent></part><relatedItem type="host"><titleInfo><title>Am J Pathol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>174</number></detail><extent unit="pages"><start>989</start><end>998</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Dendritic cells and the immunopathogenesis of idiopathic inflammatory myopathies</title></titleInfo><name type="personal"><namePart type="given">CML</namePart><namePart type="family">de Padilla</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AM</namePart><namePart type="family">Reed</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">de Padilla CML, Reed AM. Dendritic cells and the immunopathogenesis of idiopathic inflammatory myopathies. Curr Opin Rheumatol 2008;20:669–674.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>669</start><end>674</end></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Rheumatol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>669</start><end>674</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Gilliet</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Cao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y‐J</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gilliet M, Cao W, Liu Y‐J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008;8:594–606.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>594</start><end>606</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Rev Immunol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>594</start><end>606</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Swiecki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Colonna</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 2010;234:142–162.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>234</number></detail><extent unit="pages"><start>142</start><end>162</end></extent></part><relatedItem type="host"><titleInfo><title>Immunol Rev</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>234</number></detail><extent unit="pages"><start>142</start><end>162</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">CM</namePart><namePart type="family">López de Padilla</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AN</namePart><namePart type="family">Vallejo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KT</namePart><namePart type="family">McNallan</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">López de Padilla CM, Vallejo AN, McNallan KT et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 2007;56:1658–1668.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>1658</start><end>1668</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>1658</start><end>1668</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Shrestha</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Wershil</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JF</namePart><namePart type="family">Sarwark</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shrestha S, Wershil B, Sarwark JF et al. Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum 2010;62:2813–2822.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>2813</start><end>2822</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>2813</start><end>2822</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>An interferon aignature in the peripheral blood of dermatomyositis patients is associated with disease activity</title></titleInfo><name type="personal"><namePart type="given">EC</namePart><namePart type="family">Baechler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JW</namePart><namePart type="family">Bauer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CA</namePart><namePart type="family">Slattery</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baechler EC, Bauer JW, Slattery CA et al. An interferon aignature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007;13:59–68.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>59</start><end>68</end></extent></part><relatedItem type="host"><titleInfo><title>Mol Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>59</start><end>68</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit25"><titleInfo><title>Elevated serum interferon‐alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty‐six months of therapy</title></titleInfo><name type="personal"><namePart type="given">TB</namePart><namePart type="family">Niewold</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SN</namePart><namePart type="family">Kariuki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GA</namePart><namePart type="family">Morgan</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Niewold TB, Kariuki SN, Morgan GA et al. Elevated serum interferon‐alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty‐six months of therapy. Arthritis Rheum 2009;60:1815–1824.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1815</start><end>1824</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1815</start><end>1824</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit26"><titleInfo><title>Interferon‐stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Salajegheh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SW</namePart><namePart type="family">Kong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JL</namePart><namePart type="family">Pinkus</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Salajegheh M, Kong SW, Pinkus JL et al. Interferon‐stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010;67:53–63.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>53</start><end>63</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Neurol</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>53</start><end>63</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit27"><titleInfo><title>Analysis of lymphocyte subpopulations in peripheral blood in adult and juvenile cases of dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Ishida</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Matsumoto</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Ohashi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ishida T, Matsumoto Y, Ohashi M et al. Analysis of lymphocyte subpopulations in peripheral blood in adult and juvenile cases of dermatomyositis. J Dermatol 1993;20:30–34.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>30</start><end>34</end></extent></part><relatedItem type="host"><titleInfo><title>J Dermatol</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>30</start><end>34</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit28"><titleInfo><title>Difference in B cell activation between dermatomyositis and polymyositis: analysis of the expression of RP105 on peripheral blood B cells</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Kikuchi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Koarada</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Tada</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kikuchi Y, Koarada S, Tada Y et al. Difference in B cell activation between dermatomyositis and polymyositis: analysis of the expression of RP105 on peripheral blood B cells. Ann Rheum Dis 2001;60:1137–1140.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1137</start><end>1140</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1137</start><end>1140</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit29"><titleInfo><title>Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group</title></titleInfo><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Artlett</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Ramos</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SA</namePart><namePart type="family">Jiminez</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Artlett CM, Ramos R, Jiminez SA et al. Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group. Lancet 2000;356:2155–2156.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>356</number></detail><extent unit="pages"><start>2155</start><end>2156</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>356</number></detail><extent unit="pages"><start>2155</start><end>2156</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit30"><titleInfo><title>Chimerism in children with juvenile dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">AM</namePart><namePart type="family">Reed</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">YJ</namePart><namePart type="family">Picornell</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Harwood</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Reed AM, Picornell YJ, Harwood A et al. Chimerism in children with juvenile dermatomyositis. Lancet 2000;356:2156–2157.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>356</number></detail><extent unit="pages"><start>2156</start><end>2157</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>356</number></detail><extent unit="pages"><start>2156</start><end>2157</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit31"><titleInfo><title>Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies</title></titleInfo><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Artlett</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FW</namePart><namePart type="family">Miller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LG</namePart><namePart type="family">Rider</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Artlett CM, Miller FW, Rider LG. Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001;40:1279–1284.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>1279</start><end>1284</end></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology (Oxford)</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>1279</start><end>1284</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit32"><titleInfo><title>Myositis‐specific autoantibodies: their clinical and pathogenic significance in disease expression</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Gunawardena</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ZE</namePart><namePart type="family">Betteridge</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NJ</namePart><namePart type="family">McHugh</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gunawardena H, Betteridge ZE, McHugh NJ. Myositis‐specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 2009;48:607.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>607</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology (Oxford)</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>607</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit33"><titleInfo><title>A new approach to the classification of idiopathic inflammatory myopathy: myositis‐specific autoantibodies define useful homogeneous patient groups</title></titleInfo><name type="personal"><namePart type="given">LA</namePart><namePart type="family">Love</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RL</namePart><namePart type="family">Leff</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DD</namePart><namePart type="family">Fraser</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Love LA, Leff RL, Fraser DD et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis‐specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>360</start></extent></part><relatedItem type="host"><titleInfo><title>Medicine (Baltimore)</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>360</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit34"><titleInfo><title>Autoantibody profiles in the sera of European patients with myositis</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Brouwer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GJ</namePart><namePart type="family">Hengstman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Vree Egberts</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brouwer R, Hengstman GJ, Vree Egberts W et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>116</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>116</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit35"><titleInfo><title>Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies</title></titleInfo><name type="personal"><namePart type="given">GJ</namePart><namePart type="family">Hengstman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Brouwer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WT</namePart><namePart type="family">Egberts</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hengstman GJ, Brouwer R, Egberts WT et al. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002;249:69.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>249</number></detail><extent unit="pages"><start>69</start></extent></part><relatedItem type="host"><titleInfo><title>J Neurol</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>249</number></detail><extent unit="pages"><start>69</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit36"><titleInfo><title>A broadened spectrum of juvenile myositis. Myositis‐specific autoantibodies in children</title></titleInfo><name type="personal"><namePart type="given">LG</namePart><namePart type="family">Rider</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FW</namePart><namePart type="family">Miller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IN</namePart><namePart type="family">Targoff</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rider LG, Miller FW, Targoff IN et al. A broadened spectrum of juvenile myositis. Myositis‐specific autoantibodies in children. Arthritis Rheum 1994;37:1534.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>1534</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>1534</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit37"><titleInfo><title>Clinical significance of specific autoantibodies in juvenile dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">BM</namePart><namePart type="family">Feldman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Reichlin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RM</namePart><namePart type="family">Laxer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Feldman BM, Reichlin M, Laxer RM et al. Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol 1996;23:1794.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1794</start></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1794</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit38"><titleInfo><title>HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis‐scleroderma overlap</title></titleInfo><name type="personal"><namePart type="given">LR</namePart><namePart type="family">Wedderburn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NJ</namePart><namePart type="family">McHugh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Chinoy</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wedderburn LR, McHugh NJ, Chinoy H et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis‐scleroderma overlap. Rheumatology (Oxford) 2007;46:1786.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1786</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology (Oxford)</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1786</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit39"><titleInfo><title>The dermatomyositis‐specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Zhang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">LeRoy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HP</namePart><namePart type="family">Seelig</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zhang Y, LeRoy G, Seelig HP et al. The dermatomyositis‐specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 1998;95:279.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>95</number></detail><extent unit="pages"><start>279</start></extent></part><relatedItem type="host"><titleInfo><title>Cell</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>95</number></detail><extent unit="pages"><start>279</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit40"><titleInfo><title>Anti‐signal recognition particle autoantibodies: marker of a necrotising myopathy</title></titleInfo><name type="personal"><namePart type="given">GJ</namePart><namePart type="family">Hengstman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HJ</namePart><namePart type="family">ter Laak</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WT</namePart><namePart type="family">Vree Egberts</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hengstman GJ, ter Laak HJ, Vree Egberts WT et al. Anti‐signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006;65:1635.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>1635</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>1635</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit41"><titleInfo><title>Myopathy with antibodies to the signal recognition particle: clinical and pathological features</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Miller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MT</namePart><namePart type="family">Al‐Lozi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Lopate</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Miller T, Al‐Lozi MT, Lopate G et al. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002;73:420.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><extent unit="pages"><start>420</start></extent></part><relatedItem type="host"><titleInfo><title>J Neurol Neurosurg Psychiatry</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><extent unit="pages"><start>420</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit42"><titleInfo><title>Autoantibody to signal recognition particle in African American girls with juvenile polymyositis</title></titleInfo><name type="personal"><namePart type="given">KA</namePart><namePart type="family">Rouster‐Stevens</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LM</namePart><namePart type="family">Pachman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rouster‐Stevens KA, Pachman LM. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol 2008;35:927.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>927</start></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>927</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit43"><titleInfo><title>Autoantibodies to transcriptional intermediary factor 1‐gamma (TIF1‐g) in dermatomyositis. Abstract</title></titleInfo><name type="personal"><namePart type="given">IN</namePart><namePart type="family">Targoff</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EP</namePart><namePart type="family">Trieu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Levy‐Neto</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Targoff IN, Trieu EP, Levy‐Neto M et al. Autoantibodies to transcriptional intermediary factor 1‐gamma (TIF1‐g) in dermatomyositis. Abstract. Arthritis Rheum 2006;54:S518.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>S518</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>S518</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit44"><titleInfo><title>FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Dupont</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Mamidi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Cordenonsi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dupont S, Mamidi A, Cordenonsi M et al. FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 2009;136:123.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>136</number></detail><extent unit="pages"><start>123</start></extent></part><relatedItem type="host"><titleInfo><title>Cell</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>136</number></detail><extent unit="pages"><start>123</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit45"><titleInfo><title>Association of distinct clinical subsets with myositis‐specific autoantibodies towards anti‐155/140‐kDa polypeptides, anti‐140‐kDa polypeptides, and anti‐aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single‐centre, cross‐sectional study</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Fujikawa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Kawakami</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Kaji</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fujikawa K, Kawakami A, Kaji K et al. Association of distinct clinical subsets with myositis‐specific autoantibodies towards anti‐155/140‐kDa polypeptides, anti‐140‐kDa polypeptides, and anti‐aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single‐centre, cross‐sectional study. Scand J Rheumatol 2009;38:263.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><extent unit="pages"><start>263</start></extent></part><relatedItem type="host"><titleInfo><title>Scand J Rheumatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><extent unit="pages"><start>263</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit46"><titleInfo><title>Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Kaji</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Fujimoto</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Hasegawa</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kaji K, Fujimoto M, Hasegawa M et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007;46:25.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>25</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology (Oxford)</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>25</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit47"><titleInfo><title>A novel autoantibody to a 155‐kd protein is associated with dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">IN</namePart><namePart type="family">Targoff</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Mamyrova</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EP</namePart><namePart type="family">Trieu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Targoff IN, Mamyrova G, Trieu EP et al. A novel autoantibody to a 155‐kd protein is associated with dermatomyositis. Arthritis Rheum 2006;54:3682.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>3682</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>3682</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit48"><titleInfo><title>Cancer‐associated myositis and anti‐p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Trallero‐Araguas</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Labrador‐Horrillo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Selva‐O’Callaghan</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Trallero‐Araguas E, Labrador‐Horrillo M, Selva‐O’Callaghan A et al. Cancer‐associated myositis and anti‐p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 2010;89:47.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>89</number></detail><extent unit="pages"><start>47</start></extent></part><relatedItem type="host"><titleInfo><title>Medicine (Baltimore)</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>89</number></detail><extent unit="pages"><start>47</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit49"><titleInfo><title>Anti‐MDA5 and anti‐TIF1‐gamma antibodies have clinical significance for patients with dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Hoshino</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Muro</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Sugiura</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hoshino K, Muro Y, Sugiura K et al. Anti‐MDA5 and anti‐TIF1‐gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 2010;49:1726.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>1726</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology (Oxford)</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>1726</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit50"><titleInfo><title>Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Gunawardena</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LR</namePart><namePart type="family">Wedderburn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">North</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gunawardena H, Wedderburn LR, North J et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008;47:324.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>324</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology (Oxford)</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>324</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit51"><titleInfo><title>Clinical and serological characterisation of the anti‐MJ antibody in childhood myositis. Abstract</title></titleInfo><name type="personal"><namePart type="given">CV</namePart><namePart type="family">Oddis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Fertig</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Goel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Oddis CV, Fertig N, Goel A et al. Clinical and serological characterisation of the anti‐MJ antibody in childhood myositis. Abstract. Arthritis Rheum 1997;40(Suppl):S139.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><detail type="issue"><caption>no.</caption><number>Suppl</number></detail><extent unit="pages"><start>S139</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><detail type="issue"><caption>no.</caption><number>Suppl</number></detail><extent unit="pages"><start>S139</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit52"><titleInfo><title>Sera with autoantibodies to the MJ antigen react with NXP2. Abstract</title></titleInfo><name type="personal"><namePart type="given">IN</namePart><namePart type="family">Targoff</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EP</namePart><namePart type="family">Trieu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Levy‐Neto</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Targoff IN, Trieu EP, Levy‐Neto M et al. Sera with autoantibodies to the MJ antigen react with NXP2. Abstract. Arthritis Rheum 2007;56:S787.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>S787</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>S787</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit53"><titleInfo><title>Autoantibodies to a 140‐kd protein in juvenile dermatomyositis are associated with calcinosis</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Gunawardena</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LR</namePart><namePart type="family">Wedderburn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Chinoy</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gunawardena H, Wedderburn LR, Chinoy H et al. Autoantibodies to a 140‐kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009;60:1807.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1807</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1807</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit54"><titleInfo><title>RNA helicase encoded by melanoma differentiation‐associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Sato</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Hoshino</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Satoh</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sato S, Hoshino K, Satoh T et al. RNA helicase encoded by melanoma differentiation‐associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009;60:2193.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>2193</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>2193</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit55"><titleInfo><title>Myositis autoantibodies in Korean patients with inflammatory myositis: anti‐140‐kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">EH</namePart><namePart type="family">Kang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Nakashima</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Mimori</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kang EH, Nakashima R, Mimori T et al. Myositis autoantibodies in Korean patients with inflammatory myositis: anti‐140‐kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 2010;11:223.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>11</number></detail></part><relatedItem type="host"><titleInfo><title>BMC Musculoskelet Disord</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>11</number></detail></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit56"><titleInfo><title>CD20‐targeted therapy: the next generation of antibodies</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">van Meerten</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Hagenbeek</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">van Meerten T, Hagenbeek A. CD20‐targeted therapy: the next generation of antibodies. SeminHematol 2010;47:199.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>199</start></extent></part><relatedItem type="host"><titleInfo><title>SeminHematol</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>199</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit57"><titleInfo><title>Rituximab‐induced B cell depletion in autoimmune diseases: potential effects on T cells</title></titleInfo><name type="personal"><namePart type="given">SN</namePart><namePart type="family">Liossis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PP</namePart><namePart type="family">Sfikakis</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Liossis SN, Sfikakis PP. Rituximab‐induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 2008;127:280.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>127</number></detail><extent unit="pages"><start>280</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Immunol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>127</number></detail><extent unit="pages"><start>280</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit58"><titleInfo><title>A pilot study of rituximab therapy for refractory dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">TD</namePart><namePart type="family">Levine</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Levine TD. A pilot study of rituximab therapy for refractory dermatomyositis. Arthritis Rheum 2002;46:S488.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>S488</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>S488</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit59"><titleInfo><title>A pilot trial of rituximab in the treatment of patients with dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Chung</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MC</namePart><namePart type="family">Genovese</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DF</namePart><namePart type="family">Fiorentino</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007;143:763.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>143</number></detail><extent unit="pages"><start>763</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>143</number></detail><extent unit="pages"><start>763</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit60"><titleInfo><title>Rituximab in the treatment of dermatomyositis: an open‐label pilot study</title></titleInfo><name type="personal"><namePart type="given">TD</namePart><namePart type="family">Levine</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Levine TD. Rituximab in the treatment of dermatomyositis: an open‐label pilot study. Arthritis Rheum 2005;52:601.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>601</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>601</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit61"><titleInfo><title>Use of rituximab in refractory juvenile dermatomyositis. Abstract</title></titleInfo><name type="personal"><namePart type="given">LM</namePart><namePart type="family">Endo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Theos</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TP</namePart><namePart type="family">Atkinson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Endo LM, Theos A, Atkinson TP. Use of rituximab in refractory juvenile dermatomyositis. Abstract. Arthritis Rheum 2005;52:S288.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>S288</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>S288</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit62"><titleInfo><title>Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients</title></titleInfo><name type="personal"><namePart type="given">MA</namePart><namePart type="family">Cooper</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DL</namePart><namePart type="family">Willingham</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DE</namePart><namePart type="family">Brown</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cooper MA, Willingham DL, Brown DE et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007;56:3107.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>3107</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>3107</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit63"><titleInfo><title>Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases</title></titleInfo><name type="personal"><namePart type="given">HV</namePart><namePart type="family">Dinh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">McCormack</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Hall</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dinh HV, McCormack C, Hall S et al. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007;56:148.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>148</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>148</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit64"><titleInfo><title>Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Tzaribachev</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Koetter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JB</namePart><namePart type="family">Kuemmerle‐Deschner</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tzaribachev N, Koetter I, Kuemmerle‐Deschner JB et al. Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J 2009;2:6609.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>6609</start></extent></part><relatedItem type="host"><titleInfo><title>Cases J</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>6609</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit65"><titleInfo><title>Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">U</namePart><namePart type="family">Holzer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">van Royen‐Kerkhof</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">van der Torre</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Holzer U, van Royen‐Kerkhof A, van der Torre P et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol 2010;39:88.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>88</start></extent></part><relatedItem type="host"><titleInfo><title>Scand J Rheumatol</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>88</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit66"><titleInfo><title>Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials</title></titleInfo><name type="personal"><namePart type="given">RF</namePart><namePart type="family">van Vollenhoven</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Emery</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CO</namePart><namePart type="family">Bingham 3rd</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">van Vollenhoven RF, Emery P, Bingham CO 3rd et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010;37:558.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>558</start></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>558</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit67"><titleInfo><title>Rituxan [Prescribing Information]. South San Francisco, CA: Genentech Inc., 2010.</title></titleInfo><note type="citation/reference">Rituxan [Prescribing Information]. South San Francisco, CA: Genentech Inc., 2010.</note><genre>book</genre><originInfo><publisher>Genentech Inc.</publisher></originInfo><part><date>2010</date></part></relatedItem><relatedItem type="references" displayLabel="cit68"><titleInfo><title>The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta‐analysis of randomized controlled trials</title></titleInfo><name type="personal"><namePart type="given">YH</namePart><namePart type="family">Lee</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SC</namePart><namePart type="family">Bae</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GG</namePart><namePart type="family">Song</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lee YH, Bae SC, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta‐analysis of randomized controlled trials. Rheumatol Int 2010; May 16 [Epub ahead of print].</note><part><date>2010</date></part><relatedItem type="host"><titleInfo><title>Rheumatol Int</title></titleInfo><part><date>2010</date></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit69"><titleInfo><title>Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta‐analyses of randomised placebo‐controlled trials</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Salliot</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Dougados</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Gossec</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta‐analyses of randomised placebo‐controlled trials. Ann Rheum Dis 2009;68:25.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>25</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>25</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit70"><titleInfo><title>Rituximab‐associated infections</title></titleInfo><name type="personal"><namePart type="given">JC</namePart><namePart type="family">Gea‐Banacloche</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gea‐Banacloche JC. Rituximab‐associated infections. Semin Hematol 2010;47:187.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>187</start></extent></part><relatedItem type="host"><titleInfo><title>Semin Hematol</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>187</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit71"><titleInfo><title>Progressive multifocal leukoencephalopathy after rituximab therapy in HIV‐negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project</title></titleInfo><name type="personal"><namePart type="given">KR</namePart><namePart type="family">Carson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AM</namePart><namePart type="family">Evens</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EA</namePart><namePart type="family">Richey</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV‐negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>113</number></detail><extent unit="pages"><start>4834</start></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>113</number></detail><extent unit="pages"><start>4834</start></extent></part></relatedItem></relatedItem><identifier type="istex">C0CCE2C633CE41CF2E6FAF8D1F7937E04CA4A466</identifier><identifier type="ark">ark:/67375/WNG-L2HMX7R5-8</identifier><identifier type="DOI">10.1111/j.1525-1470.2011.01501.x</identifier><identifier type="ArticleID">PDE1501</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2011 Wiley Periodicals, Inc.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-16</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-L2HMX7R5-8/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000207 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000207 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:C0CCE2C633CE41CF2E6FAF8D1F7937E04CA4A466
|texte= Juvenile Dermatomyositis: Immunopathogenesis, Role of Myositis‐Specific Autoantibodies, and Review of Rituximab Use
}}
| This area was generated with Dilib version V0.6.33. |  |